Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V USA DAPT Cohort) (XVU-AV DAPT)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel
Indications Coronary artery disease; Coronary artery restenosis; Coronary stent thrombosis
Focus Adverse reactions; Therapeutic Use
Acronyms XVU-AV-DAPT
Sponsors Abbott Laboratories

Most Recent Events

01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
20 Mar 2012 Actual initiation date changed from Jul 2008 to Aug 2009 as reported by ClinicalTrials.gov.
20 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com